EGFR and non-small cell lung carcinoma: In this study, we conducted a cost‐effectiveness analysis to assess the economic viability of utilizing osimertinib in combination with chemotherapy as the initial treatment for untreated advanced non‐small cell lung cancer (NSCLC) with EGFR mutations in the United States setting based on the results from the FLAURA2 trial and the FLAURA trial.